Compared to Cluster 1 and Cluster 2 patients, Cluster 3 AML patients were characterized by older age, higher risk score, more frequent TP53 mutations, higher cytogenetics risk, and shorter OS (P values < 0.05 for all cases, Fig. 5B and Additional file 1: Table S5). This evidence concerns the gene TP53 and acute myeloid leukemia.